Assembly biosciences to present data at upcoming international herpesvirus workshop and easl congress™ 2024

-- preclinical data from both abi-5366 and abi-1179, assembly bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the international herpesvirus workshop -- -- poster accepted for presentation at easl congress™ 2024 highlights preclinical profile of abi-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis d --
ASMB Ratings Summary
ASMB Quant Ranking